Oral minoxidil significantly enhances eyelash growth, with some users experiencing increased body hair. Finasteride is used alongside to manage hair thinning, with mixed results on body hair growth.
The user reported significant hair regrowth after 8.5 months using Minoxidil, Finasteride, and initially Biotin, with a 50% reduction in the balding crown area. They are considering either a hair transplant for further improvement or embracing a bald look, feeling confident they could pull it off.
A 22-year-old user shared progress pictures after 5.5 months of using a topical solution containing Minoxidil and Finasteride for hair loss, noting increased hair density and reduced hair fall despite inconsistent application. The user recently switched to oral Dutasteride and Minoxidil due to difficulty with topical solutions and plans to update after a year.
A 31-year-old woman experienced crown hair growth using a topical solution of finasteride (0.1%) and minoxidil (5%) over five months. She applies the solution once daily, improved her fitness, and takes vitamin D and magnesium supplements.
PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.
The user shared progress pictures after 4.5 months of using 0.5 mg finasteride and 2.5 mg minoxidil daily for hair loss, considering increasing the finasteride dose after 6 months. Some attribute the improvement to the hair transplant, while others inquire about changes in crown density.
Beard gains from minoxidil are usually permanent due to facial hair follicles' lower sensitivity to DHT. Scalp hair requires ongoing DHT suppression with treatments like finasteride, dutasteride, and RU58841 to maintain gains after stopping minoxidil.
The conversation discusses hair loss treatments, including Minoxidil, finasteride, and RU58841. It also mentions ongoing human trials for hair multiplication/cloning at Yokohama National University, with skepticism about the timeline.
The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.